Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study.
Journal
Schizophrenia research and treatment
ISSN: 2090-2085
Titre abrégé: Schizophr Res Treatment
Pays: Egypt
ID NLM: 101576450
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
09
2022
revised:
26
01
2023
accepted:
29
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
There has been a recent transition from typical to atypical antipsychotics in managing schizophrenia. This has been attributed to the acute side effects experienced by patients on typical antipsychotics that lead to nonadherence. However, the treatment cost with typical antipsychotics is cheaper (preferred in low-income settings), and there is no difference in the effectiveness, efficacy, discontinuation rate, or side effect symptom burden with atypical antipsychotics. This study is aimed at determining the prevalence of nonadherence and the associated factors to typical antipsychotics among patients with schizophrenia attending a psychiatric outpatient clinic at a rural tertiary facility in Uganda. A cross-sectional study among 135 patients with schizophrenia for at least six months on typical antipsychotics (mean age of 39.7 (±11.9) and 55.6% were female) from a rural tertiary facility in Uganda. Data were collected regarding sociodemographics, adherence, insight for psychosis, attitude towards typical antipsychotics, side effects, satisfaction with medications, and explanations from health workers about medications and side effects. Logistic regression was used to determine the factors associated with nonadherence. The prevalence of nonadherence was 16.3%, and the likelihood of being nonadherent was more among the poor (monthly earning below the poverty line). However, having reduced energy was associated with reducing the likelihood of having nonadherence. The prevalence of nonadherence was lower than many previously obtained prevalence and was comparable to nonadherence for atypical antipsychotics. However, to reduce nonadherence, we need all stakeholders (such as the government, insurance companies, and caregivers) to assist patients living in poverty with access to medication.
Sections du résumé
Background
UNASSIGNED
There has been a recent transition from typical to atypical antipsychotics in managing schizophrenia. This has been attributed to the acute side effects experienced by patients on typical antipsychotics that lead to nonadherence. However, the treatment cost with typical antipsychotics is cheaper (preferred in low-income settings), and there is no difference in the effectiveness, efficacy, discontinuation rate, or side effect symptom burden with atypical antipsychotics. This study is aimed at determining the prevalence of nonadherence and the associated factors to typical antipsychotics among patients with schizophrenia attending a psychiatric outpatient clinic at a rural tertiary facility in Uganda.
Method
UNASSIGNED
A cross-sectional study among 135 patients with schizophrenia for at least six months on typical antipsychotics (mean age of 39.7 (±11.9) and 55.6% were female) from a rural tertiary facility in Uganda. Data were collected regarding sociodemographics, adherence, insight for psychosis, attitude towards typical antipsychotics, side effects, satisfaction with medications, and explanations from health workers about medications and side effects. Logistic regression was used to determine the factors associated with nonadherence.
Results
UNASSIGNED
The prevalence of nonadherence was 16.3%, and the likelihood of being nonadherent was more among the poor (monthly earning below the poverty line). However, having reduced energy was associated with reducing the likelihood of having nonadherence.
Conclusion
UNASSIGNED
The prevalence of nonadherence was lower than many previously obtained prevalence and was comparable to nonadherence for atypical antipsychotics. However, to reduce nonadherence, we need all stakeholders (such as the government, insurance companies, and caregivers) to assist patients living in poverty with access to medication.
Identifiants
pubmed: 36778520
doi: 10.1155/2023/7035893
pmc: PMC9918368
doi:
Banques de données
figshare
['10.6084/m9.figshare.19653609']
Types de publication
Journal Article
Langues
eng
Pagination
7035893Informations de copyright
Copyright © 2023 Moses Kule and Mark Mohan Kaggwa.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Curr Top Med Chem. 2021 Oct 25;21(16):1500-1516
pubmed: 34218785
JRSM Open. 2018 Apr 18;9(4):2054270418758570
pubmed: 29707225
Psychiatry Res. 2008 Nov 30;161(2):225-34
pubmed: 18922582
Trends Psychiatry Psychother. 2018 Apr-Jun;40(2):85-92
pubmed: 29768528
Psychiatry Res. 2014 May 15;216(2):263-8
pubmed: 24602993
Community Ment Health J. 2014 Oct;50(7):854-61
pubmed: 24452824
Br J Psychiatry. 2010 Jun;196(6):434-9
pubmed: 20513851
Lancet. 2012 Jun 2;379(9831):2063-71
pubmed: 22560607
Curr Drug Saf. 2019;14(3):173-181
pubmed: 30827259
Psychiatry Res. 2010 Apr 30;176(2-3):109-13
pubmed: 20185182
PLoS One. 2015 Mar 27;10(3):e0120560
pubmed: 25816353
Health Technol Assess. 2016 Sep;20(70):1-122
pubmed: 27682868
Indian J Psychol Med. 2020 Aug 20;42(5):435-444
pubmed: 33414590
Psychiatr Serv. 2016 Apr 1;67(4):431-7
pubmed: 26725294
Eur Psychiatry. 2014 Mar;29(3):191-6
pubmed: 23769325
Dialogues Clin Neurosci. 2010;12(3):345-57
pubmed: 20954430
Psychol Med. 1983 Feb;13(1):177-83
pubmed: 6133297
Eur Neuropsychopharmacol. 2012 Oct;22(10):747-50
pubmed: 22440974
Eur Neuropsychopharmacol. 2017 Oct;27(10):1064-1076
pubmed: 28755801
J Psychiatr Res. 2015 Nov;70:106-12
pubmed: 26424429
Indian J Psychol Med. 2014 Jul;36(3):294-8
pubmed: 25035554
S Afr J Psychiatr. 2018 Mar 05;24:1124
pubmed: 30263211
J Clin Psychiatry. 2006 Oct;67(10):1542-50
pubmed: 17107245
Psychiatry Clin Neurosci. 2007 Dec;61(6):587-93
pubmed: 18081617
Open Addict J. 2011 Nov 11;4:58-64
pubmed: 23264842
CNS Spectr. 2001 Apr;6(4):333-8
pubmed: 16113631
Patient Prefer Adherence. 2013 Apr 04;7:275-84
pubmed: 23589681
Acta Psychiatr Scand. 1994 Jan;89(1):62-7
pubmed: 7908156
AMA J Ethics. 2015 Nov 01;17(11):1046-52
pubmed: 26595246
Br J Psychiatry. 2003 Sep;183:197-206
pubmed: 12948991
Mol Psychiatry. 2013 Jan;18(1):53-66
pubmed: 22124274
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18
pubmed: 24167693
J Clin Psychopharmacol. 2012 Oct;32(5):602-7
pubmed: 22926592
Aust N Z J Psychiatry. 2010 Oct;44(10):921-8
pubmed: 20932206
Am J Psychiatry. 2003 Aug;160(8):1396-404
pubmed: 12900300
J Clin Psychiatry. 2006 Mar;67(3):453-60
pubmed: 16649833
Psychiatr Danub. 2015 Sep;27 Suppl 1:S266-8
pubmed: 26417777
Epidemiol Psychiatr Sci. 2014 Mar;23(1):61-70
pubmed: 23574732
Schizophr Res. 2000 May 5;42(3):241-7
pubmed: 10785582
J Postgrad Med. 2015 Oct-Dec;61(4):251-6
pubmed: 26440396
Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250
pubmed: 34025981
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
J Clin Psychiatry. 2015 Aug;76(8):e1029-34
pubmed: 26335089
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Lancet. 2022 Feb 26;399(10327):824-836
pubmed: 35219395
Brain Sci. 2021 Feb 23;11(2):
pubmed: 33672396
Patient Prefer Adherence. 2008 Feb 02;2:67-77
pubmed: 19920946